Building a healthier tomorrow

At Intercept, our focus is to develop and deliver novel medicines for those living with rare and serious liver diseases.

Bel, Living with Primary Biliary Cholangitis

Company News

Read our latest
regulatory update
Read more

Building a healthier tomorrow

At Intercept, our focus is to develop and deliver novel medicines for those living with rare liver diseases.

Innovating to solve some of today’s toughest medical challenges

Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.

  • Continuing to deliver the first and only FDA-approved FXR agonist for the second-line treatment of primary biliary cholangitis (PBC)
  • Building on our ongoing commitment to people living with PBC by progressing our research portfolio with a novel fixed-dose combination
  • Advancing our pipeline for liver diseases with high unmet need
Women

Aiming to improve lives of people with PBC

Primary biliary cholangitis (PBC) is a rare, progressive, and chronic autoimmune disease that causes bile acid to build up in the liver, resulting in inflammation and scarring (fibrosis), which, if left untreated, can lead to cirrhosis, the need for a liver transplant, or death. Therefore, we believe treatment goals should aim to prevent end-stage liver disease and in turn increase transplant-free survival.

Our whole world was turned upside down when I was diagnosed. The doctor started me on medication, and I know how important it is to get my liver function tested every few months.”

Ally

Ally, Living with PBC

Woman on Pier

Resources, connection and support for patients

We’ve gathered community resources for education, connection and support for people living with liver diseases, caregivers, family members and those interested in learning more.

  • Advancing a pipeline focused on liver diseases with high unmet need

    Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.

    View Pipeline

  • Ongoing clinical research

    Clinical trials are a critical part of developing new medicines.

    View our Clinical Trials

  • Biology in pursuit of better health

    Farnesoid X Receptor (FXR) biology is at the core of our therapeutic research. This treatment modality has applications for PBC and potentially other liver conditions, such as severe alcohol-associated hepatitis.

    Read more about our platform

Man Using Computer

About Us

Since 2002, we’ve pioneered a novel scientific platform to answer critical needs in the liver health community and deliver on our mission to build a healthier tomorrow for people with rare and serious liver diseases.

Help us help others

We’re a dynamic, fast-paced biopharmaceutical company driven by purposeful curiosity and a willingness to do things that haven’t been done before. We recognize that developing new treatments is challenging and that it takes commitment, dedication and deep scientific knowledge, but we are inspired by the opportunity to have a meaningful impact on the lives of patients. As a team, we deliver on our commitment through true collaboration and partnership.

Help

Working at Intercept

Our company started as a vision in our founder’s small New York City apartment, and we’ve kept that entrepreneurial spirit as we’ve grown to a commercial-stage company more than 300 people strong with a pipeline of innovative and investigational therapies in development.

Learn more about our culture

Leadership Team

Join our team

Our employees are collaborative, passionate and innovative. We embrace our responsibility of pioneering solutions and building hope for patients in need. If you are someone who is self-motivated and sees challenges as opportunities, join us and help us make a difference for those with rare and serious liver diseases.

View open positions